Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1989-08-09
1992-06-23
Nucker, Christine
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
4352528, 4352534, 424 93H, A61K 3909, A61K 39112
Patent
active
051241536
ABSTRACT:
Non-virulent bacteria are disclosed into which have been cloned heterologous nucleotide sequences encoded for the expression of Streptococcal M protein antigens, which are effective to elicit opsonic antibodies against Streptococcal infections. These bacteria are useful for vaccination against Streptococcus pyogenes bacteria.
REFERENCES:
patent: 4404186 (1983-09-01), Ron
patent: 4454121 (1984-06-01), Beachy
patent: 4550081 (1985-10-01), Stocker
patent: 4597967 (1986-07-01), Beachey et al.
patent: 4681762 (1987-07-01), Oeschger
patent: 4735801 (1988-04-01), Stocker
patent: 4764370 (1988-08-01), Fields
patent: 4784948 (1988-11-01), Scott
patent: 4888170 (1989-12-01), Curtiss
patent: 4919930 (1990-04-01), Beachy
patent: 4968619 (1990-04-01), Curtiss
Bacterial Vaccines, 1984. Rene Germanier, editor. Academic Press, New York. Chapter 5 "Typhoid Fever".
A. Brown et al., J. Infect Dis. 155(1):86-92. An attenuated aro A salmonella typhimurium . . .
Hogeth, S. et al., Nature 291:238-39, Aromatic dependent S. typhimurium are non-virulent . . .
In-Vivo Immunostimulating Activity of the 163-171 Peptide of Human Nencioni L. et al., J. Immunol 139 (3) 1987, 800-804.
Primary Prophylaxis of Rheumatic Fever State and Prospects Vaccine Inst. Hyg. Epidemiol., Prague, Czech, Ter Arkh 57 (11) 1985, 97-100.
Expression of Mycobacterium-Leprae Genes from a Streptococcus-Mutan Jacobs W R. et al., Proc. Natl. Acad. Sci. USA 83 (6) 1986, 1926-193.
In-Vivo Repackaging of Recombinant Cosmid Molecules for Analysis Salmonella-Typhimurium Strptococcus-Mutans and Mycobacerial Genom Jacobs W R., Infect. Immun., 52 (1) 1986 101-109.
Use of MuramylDipeptides in the Synthetic Vaccine Models Audibert F., Boll 1st Sieroter Milan, 64 (2). 1985. 95-102.
Molecular Analysis of DNA and Construction of Genomic Libraries of . . . Clark-Curtiss J. E. et al., J. Bacteriol 161 (3). 1985, 1093-1102.
Mono Clonal Antibodies to Streptococcal Group A Carbohydrate 2 . . . Fulton R. J. et al., J. Immunol., 131 (3). 1983. 1326-1331.
Cloning Virulence Determinants from Streptococcus Mutans and the use Hamada, Mol. Microbiol, 1986. 173-80.
Type Specific Protective Immunity Evoked by Snythetic Peptide of S. Pyogenes M.Protein (Nature, v. 292, No. 5822, Jul. 30, 1981 Beachey et al.
Expression of Protective and Cardiac Tissue Cross-Reactive Epitopes of Type 5 Streptoccal M Protein in E. coli, Infec. and Immun, 1985).
Cloning and Genetic Analysis of Serotype 5 M Protein Determinant of Group A Streptococci: Infec. and Immun. (1985) p. 190-197.
Cloning Virulence Determinants from S. Mutans and the use of Recombinant Clones to Construct Bivalent Oral Vaccine Strains to confer Protective Immunity against S. Mutains-Induced Dental Caries, (1988), Elsevia Science Publishers, p. 173-180.
Beachey Edwin H.
Kehoe Michael A.
Poirier Thomas P.
Cunningham T. M.
Nucker Christine
University of Tennessee Research Corp.
LandOfFree
Therapeutic compositions against streptococcal infections, trans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions against streptococcal infections, trans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions against streptococcal infections, trans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-931795